BioPharma Dive August 15, 2022
Christopher Newman

The main U.S. drug lobby has said it will push back against the legislation, which includes policies that drugmakers have opposed for decades.

The pharmaceutical industry is gearing up to minimize the effect of major drug legislation passed by Congress on Friday, the first time in many years lawmakers have overcome the drug lobby’s opposition to limits on their pricing power.

On Friday, the House of Representatives passed the Inflation Reduction Act in a 220-207 party-line vote, sending the bill to President Joe Biden for his signature this week.

“Make no mistake. These measures are a big blow to pharma, which has had a stranglehold for decades, preventing us from making this move,” House Speaker Nancy Pelosi, D-Calif., said in...

Today's Sponsors

pCare
Institute for Healthcare Improvement
Crossover Health

Today's Sponsors

ZeOmega
Holon

Today's Sponsor

Premier

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations
HHS reports surge in drug prices over past year
Delays in FDA's accelerated approval drugs cost US $18B
Hollywood and the Metaverse’s effect on pharma’s content
Gaps in clinical trial diversity remain in spite of efforts to raise awareness, encourage participation
Accommodations Increase Clinical Trial Participation for Patients of Color, Survey Reveals